Management of Occupational and Nonoccupational HIV Exposure

  • Author: Christopher B. Hurt, MD (More Info)
  • Editors In Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 8/1/18 (What's New)

Summary

  • Only clinical efficacy data available for PEP come from CDC’s case-control database of exposed healthcare workers and seroconverters[Cardo 1997; Do 2003]
  • Rationale for recommending PEP:
    • Administration of tenofovir DF–based PEP within first 24-36 hours of vaginal exposure in macaque model prevented infection[Otten 2000]

Action required

©2020 Clinical Care Options, LLC. All Rights Reserved.

The materials published via inPractice® reflect the views of the reviewers or authors of the material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.